Company / Free Cash Flow
Crinetics Pharmaceuticals, Inc. Free Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$383.7M
FY2025
5-year range
-$383.7M / -$89.0M
FY2021-FY2025
Trend
-63.9%
vs FY2024
Sector context
#181 of 194
Health Care
What the data says
Among 194 Health Care companies, Crinetics Pharmaceuticals, Inc. is in the bottom 7% for free cash flow. Free Cash Flow has declined for 7 consecutive years, from -$6M in FY2018 to -$384M in FY2025.
Based on SEC 10-K filings.
-$384M in FY2025.
Declined from -$173M to -$384M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 7% in Health CareTop 93% of 194This company -$383.7M Sector average $470.6M
▼
-181.5% below sector average
Key checks
Key Insights
- Crinetics Pharmaceuticals, Inc.'s free cash flow has declined for 7 consecutive years.
- In FY2025, free cash flow decreased 63.9% year-over-year.
- Ranks #181 out of 194 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$383.7M | -63.9% |
| FY2024 | -$234.0M | -35.1% |
| FY2023 | -$173.3M | -48.3% |
| FY2022 | -$116.9M | -31.3% |
| FY2021 | -$89.0M | -333.9% |
| FY2020 | -$20.5M | -109.7% |
| FY2019 | -$9.8M | -72.9% |
| FY2018 | -$5.7M | +42.2% |
| FY2017 | -$9.8M | -72.9% |
| FY2016 | -$5.7M | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026